PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 21258173-7 2011 Furthermore, these expressions were completely recovered to normal levels by orexin-A and were reversed by the administration of SB334867, a specific orexin-1 receptor antagonist. 1-(2-methylbenzoxazol-6-yl)-3-(1,5)naphthyridin-4-yl urea 129-137 hypocretin Mus musculus 77-85 23117790-10 2013 The MCAO-induced decrease in insulin receptor levels in the liver and skeletal muscle on day 1 was recovered to control levels by orexin-A, and this effect of orexin-A was reversed by the administration of SB334867 as well as by hypothalamic BDNF knockdown. 1-(2-methylbenzoxazol-6-yl)-3-(1,5)naphthyridin-4-yl urea 206-214 hypocretin Mus musculus 159-167 20034477-4 2010 C57BL/6J mice received the orexin receptor 1 (Ox1r) antagonist, SB-334867, prior to test sessions. 1-(2-methylbenzoxazol-6-yl)-3-(1,5)naphthyridin-4-yl urea 64-73 hypocretin Mus musculus 27-33 19915095-5 2010 This action of orexin A was blocked by SB334867, an orexin receptor 1 (OXR1) blocker and bisindolylmaleimide, a protein kinase C (PKC) inhibitor, indicating the involvement of OXR1 and PKC. 1-(2-methylbenzoxazol-6-yl)-3-(1,5)naphthyridin-4-yl urea 39-47 hypocretin Mus musculus 15-23 16762378-7 2006 The OXA-induced contraction was significantly inhibited by hexamethonium and SB-334867-A, whereas the nicotine-induced contraction was not inhibited by SB-334867-A. 1-(2-methylbenzoxazol-6-yl)-3-(1,5)naphthyridin-4-yl urea 77-86 hypocretin Mus musculus 4-7 19809293-11 2009 Microinjection of the orexin-1 receptor antagonist SB-334867-A during the active period slowed firing rates of locus coeruleus neurons in halothane-anesthetized rats, but had no effect on isoflurane-anesthetized rats. 1-(2-methylbenzoxazol-6-yl)-3-(1,5)naphthyridin-4-yl urea 51-62 hypocretin Mus musculus 22-28 16762378-11 2006 Exogenous OXA, in the presence of atropine, induced a relaxation that was significantly inhibited by both l-nitroarginine and SB-334867-A, but not by hexamethonium. 1-(2-methylbenzoxazol-6-yl)-3-(1,5)naphthyridin-4-yl urea 126-137 hypocretin Mus musculus 10-13 16867176-7 2006 Intraperitoneal injections of the HCRT-1 receptor antagonist, SB-334867, exhibited a general trend towards increasing time spent low-arched back nursing (P = 0.053) and decreasing licking and grooming of pups while high-arched back nursing (P = 0.052). 1-(2-methylbenzoxazol-6-yl)-3-(1,5)naphthyridin-4-yl urea 62-71 hypocretin Mus musculus 34-38 32575773-6 2020 OX-A-induced neuroprotection was mediated by the phosphoinositide-3-kinase/Akt (PI3K/Akt) survival pathway since both OX-A and ACEA induced phosphorylation of Akt and prevented OGD-induced cytochrome c release from the mitochondria, in a manner counteracted by SB334867 or AM251. 1-(2-methylbenzoxazol-6-yl)-3-(1,5)naphthyridin-4-yl urea 261-269 hypocretin Mus musculus 0-4 16407535-5 2006 An intra-VTA injection of a selective orexin receptor antagonist SB334867A [1-(2-methylbenzoxazol-6-yl)-3-[1.5]naphthyridin-4-yl urea] significantly suppressed the morphine-induced place preference in rats. 1-(2-methylbenzoxazol-6-yl)-3-(1,5)naphthyridin-4-yl urea 65-74 hypocretin Mus musculus 38-44 16407535-5 2006 An intra-VTA injection of a selective orexin receptor antagonist SB334867A [1-(2-methylbenzoxazol-6-yl)-3-[1.5]naphthyridin-4-yl urea] significantly suppressed the morphine-induced place preference in rats. 1-(2-methylbenzoxazol-6-yl)-3-(1,5)naphthyridin-4-yl urea 76-133 hypocretin Mus musculus 38-44 17192702-6 2006 Administration of 1 microM OX1R antagonist, SB-334867, completely blocked the observed orexin A responses in these cells, indicating that orexin A stimulation of GnRH neurons is specifically through OX1R. 1-(2-methylbenzoxazol-6-yl)-3-(1,5)naphthyridin-4-yl urea 44-53 hypocretin Mus musculus 87-95 17192702-6 2006 Administration of 1 microM OX1R antagonist, SB-334867, completely blocked the observed orexin A responses in these cells, indicating that orexin A stimulation of GnRH neurons is specifically through OX1R. 1-(2-methylbenzoxazol-6-yl)-3-(1,5)naphthyridin-4-yl urea 44-53 hypocretin Mus musculus 138-146 33139319-4 2020 Exposure to orexin-receptor antagonism (1 mg/kg SB334867, an orexin 1 receptor antagonist) just prior to cocaine-conditioning trials or the post-conditioning test, attenuated SD-enhanced preference. 1-(2-methylbenzoxazol-6-yl)-3-(1,5)naphthyridin-4-yl urea 48-56 hypocretin Mus musculus 12-18 32575773-3 2020 OGD-induced reactive oxygen species (ROS) accumulation and neuronal death were prevented by both OX-A and arachidonyl-2"-chloroethylamide (ACEA), a synthetic CB1 receptor agonist, in a manner sensitive to OX-1R and CB1 receptor antagonists, SB334867 and AM251. 1-(2-methylbenzoxazol-6-yl)-3-(1,5)naphthyridin-4-yl urea 241-249 hypocretin Mus musculus 97-101 32575773-6 2020 OX-A-induced neuroprotection was mediated by the phosphoinositide-3-kinase/Akt (PI3K/Akt) survival pathway since both OX-A and ACEA induced phosphorylation of Akt and prevented OGD-induced cytochrome c release from the mitochondria, in a manner counteracted by SB334867 or AM251. 1-(2-methylbenzoxazol-6-yl)-3-(1,5)naphthyridin-4-yl urea 261-269 hypocretin Mus musculus 118-122 28453642-5 2017 Results: Treatment with the orexin-1 receptor antagonist SB334867 increased the activity of basolateral amygdala neurons projecting to infralimbic medial prefrontal cortex during fear extinction. 1-(2-methylbenzoxazol-6-yl)-3-(1,5)naphthyridin-4-yl urea 57-65 hypocretin Mus musculus 28-34 31029425-6 2019 Icv injection of an orexin receptor antagonist, SB334867 reduced STAT3 phosphorylation, which was enhanced by icv injection of orexin but not by direct injection of orexin into MBH. 1-(2-methylbenzoxazol-6-yl)-3-(1,5)naphthyridin-4-yl urea 48-56 hypocretin Mus musculus 20-26 31029425-6 2019 Icv injection of an orexin receptor antagonist, SB334867 reduced STAT3 phosphorylation, which was enhanced by icv injection of orexin but not by direct injection of orexin into MBH. 1-(2-methylbenzoxazol-6-yl)-3-(1,5)naphthyridin-4-yl urea 48-56 hypocretin Mus musculus 127-133 31029425-6 2019 Icv injection of an orexin receptor antagonist, SB334867 reduced STAT3 phosphorylation, which was enhanced by icv injection of orexin but not by direct injection of orexin into MBH. 1-(2-methylbenzoxazol-6-yl)-3-(1,5)naphthyridin-4-yl urea 48-56 hypocretin Mus musculus 127-133 30399595-3 2019 administration of orexin 1 (OX1) receptor antagonist -SB334867- alone or in combination with NO agents on depression using the forced swimming test (FST), tail suspension test (TST) and the number of crossings in open-field test (OFT) in mice. 1-(2-methylbenzoxazol-6-yl)-3-(1,5)naphthyridin-4-yl urea 54-62 hypocretin Mus musculus 18-24 30524223-10 2018 Furthermore, the protective effects of orexin-A on MPTP parkinsonian mice could be blocked by orexinergic receptor 1 (OX1R) antagonist, SB334867. 1-(2-methylbenzoxazol-6-yl)-3-(1,5)naphthyridin-4-yl urea 136-144 hypocretin Mus musculus 39-47 29557083-0 2018 SB-334867 (an Orexin-1 Receptor Antagonist) Effects on Morphine-Induced Sensitization in Mice-a View on Receptor Mechanisms. 1-(2-methylbenzoxazol-6-yl)-3-(1,5)naphthyridin-4-yl urea 0-9 hypocretin Mus musculus 14-20 29557083-1 2018 The present study focused upon the role of SB-334867, an orexin-1 receptor antagonist, in the acquisition of morphine-induced sensitization to locomotor activity in mice. 1-(2-methylbenzoxazol-6-yl)-3-(1,5)naphthyridin-4-yl urea 43-52 hypocretin Mus musculus 57-63 29964087-5 2018 Binding of OXA to OX1R was blocked using an OX1R antagonist, SB-334867. 1-(2-methylbenzoxazol-6-yl)-3-(1,5)naphthyridin-4-yl urea 61-70 hypocretin Mus musculus 11-14 28453642-7 2017 Conclusions: These data identify neuronal circuits and cell populations of the amygdala associated with the facilitation of fear extinction consolidation induced by the orexin-1 receptor antagonist SB334867. 1-(2-methylbenzoxazol-6-yl)-3-(1,5)naphthyridin-4-yl urea 198-206 hypocretin Mus musculus 169-175 27436148-5 2016 FRET and co-immunoprecipitation experiments showed the formation of OX-1R/CB1R heteromers after incubation with OX-A (0.2muM), or OX-A (0.1muM)+ACEA (0.1muM), but not after ACEA (0.2muM), in a manner antagonized by SB-334867 or AM251. 1-(2-methylbenzoxazol-6-yl)-3-(1,5)naphthyridin-4-yl urea 215-224 hypocretin Mus musculus 112-116 28353077-5 2017 RECENT FINDINGS: In normal rats and mice, central administration of orexin increases food intake, blood pressure, and sympathetic nerve activity and these effects are blocked by selective orexin receptor antagonist SB-334867 or almorexant. 1-(2-methylbenzoxazol-6-yl)-3-(1,5)naphthyridin-4-yl urea 215-224 hypocretin Mus musculus 68-74 28353077-5 2017 RECENT FINDINGS: In normal rats and mice, central administration of orexin increases food intake, blood pressure, and sympathetic nerve activity and these effects are blocked by selective orexin receptor antagonist SB-334867 or almorexant. 1-(2-methylbenzoxazol-6-yl)-3-(1,5)naphthyridin-4-yl urea 215-224 hypocretin Mus musculus 188-194 26562300-6 2016 For this, binding of OXA to OX1R was blocked using OX1R specific antagonist, SB-334867. 1-(2-methylbenzoxazol-6-yl)-3-(1,5)naphthyridin-4-yl urea 77-86 hypocretin Mus musculus 21-24 27751532-10 2016 Conversely, pre-test injection of SB-334867 (10, 20 and 40nmol, intra-CA1) inhibited the orexin-1-induced potentiation of morphine state-dependent learning on the test day. 1-(2-methylbenzoxazol-6-yl)-3-(1,5)naphthyridin-4-yl urea 34-43 hypocretin Mus musculus 89-95 26965217-4 2016 Orexin A ( 30 nM) attenuated LTP induced by theta burst stimulation (TBS) in a manner antagonized by an OX1R (SB-334867), but not OX2R (EMPA), antagonist. 1-(2-methylbenzoxazol-6-yl)-3-(1,5)naphthyridin-4-yl urea 110-119 hypocretin Mus musculus 0-8 27436148-5 2016 FRET and co-immunoprecipitation experiments showed the formation of OX-1R/CB1R heteromers after incubation with OX-A (0.2muM), or OX-A (0.1muM)+ACEA (0.1muM), but not after ACEA (0.2muM), in a manner antagonized by SB-334867 or AM251. 1-(2-methylbenzoxazol-6-yl)-3-(1,5)naphthyridin-4-yl urea 215-224 hypocretin Mus musculus 130-134 25586545-10 2015 The OX1R antagonist SB334867 (10-6 M) and AKT antagonist PF-04691502 (10-6 M), when used individually or in combination, abolished the effect of orexin A (10-8 M) on BGC-823 cells. 1-(2-methylbenzoxazol-6-yl)-3-(1,5)naphthyridin-4-yl urea 20-28 hypocretin Mus musculus 145-153 24930888-6 2014 The extinction-facilitating effects of the hypocretin receptor-1 antagonist SB334867 were associated with increased expression of cFos in the basolateral amygdala and the infralimbic cortex. 1-(2-methylbenzoxazol-6-yl)-3-(1,5)naphthyridin-4-yl urea 76-84 hypocretin Mus musculus 43-53 24466352-5 2014 Moreover, orexin signaling blockade, with the orexin 1 receptor antagonist SB-334867, reduces acute HFD consumption and c-Fos induction in the VTA but not in the other mesolimbic nuclei under study. 1-(2-methylbenzoxazol-6-yl)-3-(1,5)naphthyridin-4-yl urea 75-84 hypocretin Mus musculus 10-16 25107627-11 2014 Orexin-1 but not 2 receptor antagonism with SB334867 (10muM; n=9) and TCS-OX2-29 (2muM; n=5), respectively, blocks the effects of decreased glucose on VTA DA neurons. 1-(2-methylbenzoxazol-6-yl)-3-(1,5)naphthyridin-4-yl urea 44-52 hypocretin Mus musculus 0-6 24466352-5 2014 Moreover, orexin signaling blockade, with the orexin 1 receptor antagonist SB-334867, reduces acute HFD consumption and c-Fos induction in the VTA but not in the other mesolimbic nuclei under study. 1-(2-methylbenzoxazol-6-yl)-3-(1,5)naphthyridin-4-yl urea 75-84 hypocretin Mus musculus 46-52 23880022-7 2013 In the second experiment, mice were treated as in Experiment 1 and type 1 orexin receptor antagonist, SB334867 (20mg/kg), was administered before the ethanol challenge successfully blocking the expression of sensitization in mice chronically treated with EtOH. 1-(2-methylbenzoxazol-6-yl)-3-(1,5)naphthyridin-4-yl urea 102-110 hypocretin Mus musculus 74-80